About Gliacure
GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has(...)
Our Approach
GliaCure’s goals are based on the premise that glia are an untapped resource for drug discovery. The brain is composed of two cell types: the much-studied and electrically active neurons and glia, a second cell type that is electrically inactive. For many years work in the(...)
About Glia
For much of the past century the focus of neuroscience was on the role of neurons in brain function. This bias was based on technical limitations. In the first half of the 20th century electrical recording and stimulation techniques were available; consequently, scientists(...)